1.Analysis of the status quo of self-perception and its influencing factors in Changsha elderly
Zemei XIAO ; Junyang YIN ; Dan CHEN ; Jiayi PENG ; Shi TANG
Chinese Journal of Practical Nursing 2022;38(11):801-806
Objective:To investigate the self-perceived aging status of the elderly in Changsha and analyze its influencing factors.Methods:From July to August in 2020, the convenient sampling method was used to select 402 elderly people in Changsha as the research object, the general data questionnaire, the elderly self-perceived aging questionnaire, the family care questionnaire and the positive psychological capital questionnaire were used to investigate them. Multiple linear regression analysis was used to analyze the influencing factors of self-perceived aging after logarithmic transformation.Results:The total score of self-perceived aging of the elderly was 109.00(102.00, 112.00), the total score of family care was 5.00(3.00, 8.00) and the total score of psychological capital was 80.00(66.00, 87.25). Regression analysis showed that the gender, educational level, age, the forms of health care, quarrels in family relationships, children visit frequency and the degree of family care were the important factors affecting the self-perceived aging of the elderly( P<0.05). Conclusions:The self-perceived aging level of the elderly is at a medium level, it is suggested that relevant departments take comprehensive measures to create positive self-aging environment.
2.Preliminary study on clinical efficacy of intra-arterial chemotherapy and intravenous chemotherapy for unilateral advanced retinoblastoma
Dongyue LIU ; Mei JIN ; Jie YIN ; Fengxian WANG ; Lipo HAN ; Zheng WANG ; Nan ZHANG ; Junyang ZHAO ; Li LI ; Chengyue ZHANG
Chinese Journal of Ocular Fundus Diseases 2022;38(3):187-190
Objective:To compare the clinical efficacy and complications of intra-arterial chemotherapy (IAC) and intravenous chemotherapy (IVC) for unilateral advanced retinoblastoma (RB).Methods:A retrospective clinical study. From January 2020 to January 2021, 40 patients (40 eyes) unilateral group cT2 RB patients diagnosed at Baoding Children’s Hospital and Beijing Children’s Hospital were recruited in this study. There were 22 males (22 eyes) and 18 females (18 eyes). All were monocular. All the patients were assigned to two groups according to different treatment modalities they received: IVC group and IAC group. There were 26 eyes and 14 eyes, respectively. When the tumor invades the optic nerve, choroid, sclera, anterior chamber and iris, enucleation was performed. The globe salvage rate, tumor extraocular metastasis rate, solid tumor control rate, treatment-related complications and pathological high-risk factors after enucleation were observed. The globe salvage rate and solid tumor control rate were compared between the groups by chi square test.Results:The globe salvage rate of IAC group and IVC group were 88.5% (23/26) and 50.0% (7/14), respectively. Solid tumor control of IAC group and IVC group were 84.6% (22/26) and 42.9% (6/14), respectively. There were statistically significant differences in globe salvage rate and solid tumor control between the two groups ( χ 2=7.18, 7.56; P<0.05). Compared with IVC group, IAC group had less systemic complications, mild ocular and periocular side effects. Among 26 cases in IAC group and 14 cases in IVC group, 3 and 7 cases underwent enucleation respectively. The results of pathological examination showed that there were 2 cases and 3 cases with pathological high-risk factors in the two groups, respectively. During the follow-up period, 2 cases in IAC group had extraocular metastasis, there was no extraocular metastasis in IVC group. Conclusion:Compared with IVC, IAC has the advantages of high tumor control rate, high globe salvage rate, less and mild complications, however, there is still tumor recurrence.
3.Quality assessment of pharmacoeconomic evaluation literature in China from 2018 to 2022
Zhixin FAN ; Junyang LIU ; Liwei ZHANG ; Xu SI ; Qing HE ; Qiang SUN ; Jia YIN
China Pharmacy 2023;34(21):2613-2619
OBJECTIVE To analyze existing problems of pharmacoeconomic evaluation research in China and to improve the standardization and scientificity of research, so as to provide more high-quality evidence for government decision-making. METHODS Retrieved from CNKI, Wanfang database, VIP, PubMed, Web of Science from 2018 to 2022, the literature related to pharmacoeconomic evaluation in China was collected; Excel 2016 software was used to extract the key information of the included literature which met inclusion criteria. The Quality of Health Economic Studies (QHES) scale was used to evaluate the quality of the included literature. RESULTS A total of 113 pieces of literature were included in this study, involving 85 pieces of Chinese literature and 28 pieces of English literature. The overall score of QHES included literature was 65.7, of which the average score of Chinese literature was 62.0 and English literature was 76.9. The median quality scores for the literature in 2018, 2019, 2020, 2021 and 2022 were 62.0, 70.5, 59.3, 71.0, and 73.0, respectively. Of these, 65 pieces of literature reported the research perspective; 36 reported the discount rate indistinctly; 25 provided unclear definitions of thresholds; and 53 used two sensitivity analysis methods. Among different items of the QHES scale, item 2 (research perspective), item 8 (time range and discount rate), item 14 (potential bias) and item 16 (sources of funding) had low percentage of scores. CONCLUSIONS From 2018 to 2022, pharmacoeconomic evaluation literature published by Chinese academics has generally shown a fluctuating upward trend in terms of quality, but there is still some room for improvement. The main problems in current pharmacoeconomics research in China include unclear understanding of the research perspective, single measurement of cost and health outcomes, unreasonable design of time horizon, indistinct description of the threshold or discount rate, and lack of sensitivity analysis.